SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ELEVIDYS as a safe and effective treatment with a clear path to broader regulatory approval. The deadline for investors with losses to be considered by the court to serve as Lead Plaintiff is August 25, 2025. Ha ...